Author

Daniele V. F. Tauriello

Erasmus MCORCID 0000-0003-1522-3496Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Eduard BatlleiD· 2 shared Alex BoussioutasiD· 1 shared Amr H. AllamiD· 1 shared Ana Raquel HenriquesiD· 1 shared Anne Huber· 1 shared Antoni RiéraiD· 1 shared Ashleigh R. PohiD· 1 shared Carolina SáncheziD· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Eduard BatlleORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologyACS Pharmacology & Translational SciencePeer-reviewedOct 1, 2024

HYL001, a new potent TGFβ signaling inhibitor that is efficacious against microsatellite stable CRC metastasis in combination with immune checkpoint therapy in mice

Daniele V. F. Tauriello, Elena Sancho, Daniel Byrom…·Antoni Riéra

This paper describes the development of HYL001, a TGFβ inhibitor that effectively combats microsatellite stable CRC metastasis in mice when combined with immune checkpoint therapy.

6 citations

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyCell ReportsPeer-reviewedAug 1, 2024

Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within Interleukin-6 family cytokines

Anne Huber, Amr H. Allam, Christine Dijkstra…·Moritz F. Eissmann

This study identifies IL6/STAT3 signaling as a therapeutic target for TP53-mutant gastric cancer by showing its role in metastatic progression driven by mutant Trp53.

20 citations

mouseexperimental assay

𝕏 PostBluesky